Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.14670/HH-18-657

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorWang, Min-
dc.contributor.authorLiu, Kai-
dc.contributor.authorZhou, Zhongming-
dc.contributor.authorGeng, Huizhuan-
dc.date.accessioned2024-04-10T08:28:05Z-
dc.date.available2024-04-10T08:28:05Z-
dc.date.issued2024-
dc.identifier.citationHistology and Histopathology Vol. 39, nº4 (2024)es
dc.identifier.issn0213-3911-
dc.identifier.issn1699-5848-
dc.identifier.urihttp://hdl.handle.net/10201/140670-
dc.description.abstractBackground. The interaction of microRNA with Chinese herbal medicines is a promising therapeutic approach for prevention of cervical cancer. Methods. Western blotting or qRT-PCR were carried out to identify the expression of NCAPG2 and miR-638. A tetrandrine (TET) cell model was used to explore the effects of miR-638 and its target gene NCAPG2 using CCK-8, transwell, wound healing, and western blot assays. Furthermore, luciferase activity assay was conducted to measure the interaction among TET, NCAPG2 and miR-638. Results. Under TET treatment, Hela and SiHa cells exhibited repressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT), and these effects were further enhanced by high expression of miR-638. In contrast, NCAPG2 expression was low in TET-treated cells and had an opposite effect to that of miR-638. Conclusion. We highlighted that miR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under tetrandrine treatmentes
dc.formatapplication/pdfes
dc.format.extent13es
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectmiR-638es
dc.subjectNCAPG2es
dc.subjectTetrandrinees
dc.subjectCervical canceres
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titlemiR-638 suppresses cervical cancer progression by inhibiting NCAPG2 under the treatment of Tetrandrinees
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doihttps://doi.org/10.14670/HH-18-657-
Aparece en las colecciones:Vol.39, nº4 (2024)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Wang-39-497-509-2024 (1).pdf8,78 MBAdobe PDFVista previa
Visualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons